Affiliation:
1. Department of Pharmaceutics, Bharat Institute of
Technology (BIT), School of Pharmacy, Meerut-250103, Uttar Pradesh, India
2. Department of Pharmaceutics, Radha Govind University, Jharkhand, India
Abstract
Abstract:
Mucormycosis is the most emerging angioinvasive fungal infection of filamentous fungi of the
Zygomycetes class, which, when neglected, causes severe disseminated infection along with significant
chances of morbidity and mortality. The diagnosis and treatment remain challenging for the doctors. It
has been observed that people who have been suffering from different diseases, such as hematological
malignancies and uncontrolled diabetes, or who have gone through different surgeries, such as hematopoietic
stem cell transplant, and solid transplantation, are the most affected ones. On the other hand, people
who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically
show the symptoms of mucormycosis after 1-2 weeks of successful recovery. Standard treatment of mucormycosis
is traditionally considered an amphotericin B intravenous (IV) drug as initial therapy, although
posaconazole and isavuconazole are also used. The core objective of the review is to typically
focus on the area of the sudden cause of mucormycosis in the patients who have already recovered from
SARS-CoV-2.
Publisher
Bentham Science Publishers Ltd.
Subject
Infectious Diseases,Pharmacology